+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

In vitro activity of gemifloxacin against clinical isolates of Neisseria gonorrhoeae with and without mutations in the gyrA gene



In vitro activity of gemifloxacin against clinical isolates of Neisseria gonorrhoeae with and without mutations in the gyrA gene



International Journal of Antimicrobial Agents 22(1): 73-76



The MIC of gemifloxacin and five other quinolones was tested against 31 clinical isolates of Neisseria gonorrhoeae; strains were analyzed for the presence of mutations in both the gyrA and parC genes. Only seven strains were resistant to nalidixic acid due to a mutation in the gyrA gene but not in the parC gene, with six and two considered intermediate to ciprofloxacin and levofloxacin, respectively. The activity of gemifloxacin was similar to that of trovafloxacin and moxifloxacin, but was more active than nalidixic acid, ciprofloxacin or levofloxacin against the gyrA mutant strains. Gemifloxacin is a valid therapeutic alternative to treat infections with N. gonorrhoeae, retaining its activity against strains already presenting a mutation in gyrA.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010811735

Download citation: RISBibTeXText

PMID: 12842332

DOI: 10.1016/s0924-8579(03)00083-9


Related references

Mutations in the gyrA and parC genes and in vitro activities of fluoroquinolones in 91 clinical isolates of Neisseria gonorrhoeae in Japan. Sexually Transmitted Diseases 31(3): 180-184, 2004

Pattern of DNA Gyra and ParC gene mutations in quinolone resistant Neisseria gonorrhoeae clinical isolates in Austria. International Journal of STD & AIDS 13(Suppl. 1): 16, 2002

In-vitro antimicrobial activity of HSR-903, a new fluoroquinolone, against clinical isolates of Neisseria gonorrhoeae with quinolone resistance-associated alterations in GyrA and ParC. Journal of Antimicrobial ChemoTherapy 40(3): 437-439, 1997

Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. ChemoTherapy 43(4): 239-244, 1997

Antimicrobial activity of gemifloxacin (SB-265805), a newer fluoroquinolone, against clinical isolates of Neisseria gonorrhoeae, including fluoroquinolone-resistant isolates. Diagnostic Microbiology and Infectious Disease 38(2): 109-113, 2000

Mutations in the gyrA and parC genes of quinolone-resistant Neisseria gonorrhoeae isolates in India. International Journal of Antimicrobial Agents 40(6): 549-553, 2012

Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates. Molecular Microbiology. 14(2): 371-380, 1994

In vitro susceptibilities of 400 Spanish isolates of Neisseria gonorrhoeae to gemifloxacin and 11 other antimicrobial agents. Antimicrobial Agents and ChemoTherapy 44(9): 2543-2544, 2000

Development of fluoroquinolone resistance and mutations involving GyrA and ParC proteins among Neisseria gonorrhoeae isolates in Japan. Journal Of Urology. 159(6): 2215-2219, E, 1998

Rapid detection of mutations of Neisseria gonorrhoeae gyrA gene using DNA chip. Zhonghua Pifuke Zazhi 37(5): 259-261, 2004

Activity of gemifloxacin tested against Neisseria gonorrhoeae isolates including antimicrobial-resistant phenotypes. Diagnostic Microbiology and Infectious Disease 54(2): 127-134, 2006